Computer adaptive testing to assess impairing behavioral health problems in emergency department patients

Lauren M. O'Reilly, BS¹; Azhar I. Dalal²; Serena Maag²; Matthew T. Perry²; Alex Card²; Max B. Bohrer²; Jackson Hamersly²; Setarah Mohammed²; Kelli Peterson²; David G. Beiser, MD, MS³; Robert D. Gibbons, PhD⁴; Brian M. D'Onofrio, PhD^{1,5}; Paul I. Musey, MD¹

Chicago IL

Corresponding author: Paul I Musey MD, Department of Emergency Medicine, 720 Eskenazi Avenue | Third Floor, Indianapolis, IN 46202; Phone: (317) 880-3900, pmusey@iu.edu

Previous Presentation: Lauren O'Reilly presented a selection of the current analyses as a poster at the IASR/AFSP International Summit on Suicide Research from October 24-27, 2021 (virtual conference). Alex Card presented a selection of the current analyses as a poster at the Society for Academic Emergency Medicine National Meeting from May 12-15, 2020 (virtual conference).

Funding: The study was supported by the Responding to the Additions Crisis Grand Challenge from Indiana University. Lauren O'Reilly was supported by the National Institute of Mental Health of the National Institutes of Health (1F31MH121039-01). Paul Musey was supported by the National Heart, Lung, and Blood Institute as a Trans NIH K12 (K12HL133310) Scholar. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The supporters had no role in the design, analysis, interpretation, or publication of this study.

Conflicts of Interest:

R. D. Gibbons is a founder of Adaptive Testing Technologies, which distributes the Computerized Adaptive Test—Mental Health suite of computerized adaptive tests (CAT-MH is a trademark of Adaptive Testing Technologies); the terms of this arrangement have been reviewed and approved by the University of Chicago in accordance with its conflicts of interest policies. The authors report no additional financial or other relationship relevant to the subject of this article.

Word count: 3.888/4000

Author Contributions: BD obtained research funding. BD, PM, and DB conceived and designed the study. PM and KP oversaw patient recruitment and managed the data. AD, SM, MP, AC, MB, JH, and SM undertook the recruitment of patients. LO analyzed the data. PM, LO, and BD drafted the manuscript, and all authors contributed substantially to the revision.

¹ Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN

² Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN

³ Section of Emergency Medicine, Department of Medicine, University of Chicago, Chicago IL ⁴ Departments of Medicine and Public Health Science (Biostatistics), University of Chicago,

⁵ Department of Medical Epidemiology & Biostatistics, Karolinska Institute, Stockholm, Sweden

Abstract

Study Objective: To assess the prevalence of several impairing behavioral health domains in stable patients presenting to the emergency department (ED) through the use of computer adaptive testing and the association among the domains, standard assessments, and ED utilization.

Methods: This was a single-center observational study of 828 randomly selected adult patients presenting to the ED from May 2019 to March 2020. The main outcomes of interest were the self-administered, validated computer adaptive assessments of suicidality, depression, anxiety, PTSD, and substance abuse using computer adaptive testing, the CAT-MHTM. We estimated the association among the CAT-MHTM subscales, standard assessments, and the number of ED visits in the year prior and 30 days after enrollment.

Results: The proportion of those who scored above the threshold of low/mild risk were: 24.1% (suicidality), 8.3% (depression), 16.5% (anxiety), 12.3% (PTSD), and 20.4% (substance use). While the CAT-MHTM subscales were highly correlated with other self-report assessments, they were not highly associated with standard ED assessments of suicidality. When examining associations with ED use, for example, individuals who had two or more ED visits in the prior year had 51% increased odds of being in the intermediate-high suicide risk category (95% Confidence Interval [CI], 1.03-2.23) compared to those with zero prior ED visits.

Conclusion: The CAT-MHTM can document the high prevalence of mental health conditions in the ED, which were missed by standard ED practices. Mental health problems are associated with ED utilization in a population of patients presenting largely for somatic complaints.

Word count: 246 / 250

Introduction

Background

There are approximately 140 million visits to US Emergency Departments (ED) annually. Visits for psychiatric or substance abuse account for approximately 10% of these visits. Importantly, this represents a dramatic rise (approximately 30%) in the number of visits primarily for mental health complaints over the past two decades, which has outpaced the rise in overall ED visitation. ED service delivery costs associated with the most prevalent mental health and substance abuse diagnoses are in excess of \$3.5 billion, with anxiety and depression accounting for \$1.7 billion annually. The severity of mental health symptomology is positively correlated with rate of ED use. 11, 12 Yet, most mental health problems are missed during ED encounters. In fact, 45% of patients who are seen in the ED for non-psychiatric primary complaints have comorbid psychiatric disorders, including major depression, general anxiety, substance abuse, and suicidal ideation.

Importance

The barriers to standard true universal mental health screening in the ED are many and include the competing priorities of ED providers providing care to critically ill patients in busy and crowded ED environments, limited access to adequate mental health resources for consultation and outpatient care, as well as the training and attitudes of ED clinicians. ^{16, 17} These same barriers have limited the approach to widespread mental health screening in the ED and represent a major missed opportunity to provide appropriate care as a significant proportion of ED patients presenting with non-psychiatric complaints have comorbid, unaddressed mental health issues as noted above. It is noteworthy that many patients who die by suicide often visit the ED or access the healthcare system shortly before their attempt for a non-psychiatric reason. ^{18, 19}

Goals of this Investigation

In this study, we build and expand upon the work of Beiser et al. (2019) who demonstrated the feasibility of using a brief computer adaptive testing tool (the CAD-MDD¹² and the CAT-DI²⁰) for depression assessment in a broad sample of ED patients with non-psychiatric primary complaints. Our objectives in this study were three-fold. First, we aimed to document the prevalence of suicidality, depression, anxiety, post-traumatic stress disorder (PTSD), and substance abuse in an ED population. Second, we compared the results of the

computer adaptive test-mental health (CAT-MHTM) standardized screening to standard of care ED assessments for suicide, as well as to other validated self-report screening tools for anxiety and depression. Finally, we aimed to estimate the health care utilization of ED patients with mental health care problems.

Methods

Sample

This was a single-center prospective observational sample of 828 randomly selected non-consecutive patients presenting at a Midwestern emergency department (ED) over the course of 10 consecutive months. This study was approved by the Indiana University School of Medicine Institutional Review Board (protocol no.1904527368) and all participants gave their informed consent. Data collection began on May 24, 2019, and ceased on March 10, 2020 with the rapid increase of COVID-19 cases and resulting stay-at-home orders. Exclusion criteria for the study included: 1) age younger than 18 years, 2) being under involuntary detention, 3) lack of or impaired decisional capacity (e.g., active psychosis, dementia, developmental delay, intoxication), 4) hemodynamic instability according to the treating provider, 5) non-English speaking, and 6) those that may encounter issues with utilization review (e.g., prisoner, living out of the state). Therefore, the cross-section of included patients were relatively stable ED subjects without overt barriers to providing consent.

Protocol

Trained research personnel used the ED tracking system within the electronic medical record (EMR) system (*Cerner Firstnet*) to screen for potentially eligible subjects presenting to the ED primarily during weekday daytime hours. To reduce sampling bias, research personnel began each screening shift by selecting a random digit between 0 and 9 using an online random number generator. All subjects on the ED census at that time with the last digit of their age matching the selected number were deemed eligible. This random selection process was repeated each time the list of eligible subjects was exhausted. The treating providers for screened subjects were approached to confirm eligibility criteria. Those subjects meeting all enrollment criteria were approached for informed consent. Participants then completed a multidimensional psychological screening using the self-administered CAT-MHTM, which is described below. Additional data including medical comorbidity, past medical history, and chief complaint were

collected and supplemented by EMR review. Socio-demographic data was collected through patient self-report. Self-reported past medical history was assessed by asking the participant to indicate if a doctor or another health care worker had diagnosed or treated the participant for 13 medical items in the past three years (see **Table 1**). Subsequently, each participant underwent a self-administered unidimensional screening for anxiety, depression, physical symptoms, and pain via a secure tablet.

Health care utilization data was obtained through the EMR and the Indiana Network for Patient Care (INPC) managed by the Indiana Health Information Exchange, the nation's largest inter-organizational clinical data repository, ²¹ to collect data regarding disposition (admit or discharge), medical history, discharge diagnoses, and ED utilization in the 12 months before and after enrollment. Note that while we intended to examine ED utilization 12 months before and after enrollment, we limited our analyses to 12 months prior and 30 days after enrollment. Research has demonstrated that the COVID-19 pandemic greatly affected health care use, particularly in EDs, ²² which would have systematically biased our long-term follow-up data.

During the study period, standard of care universal suicide screening took place at the enrollment site ED for individuals not presenting with a chief complaint of suicidal ideation. The standard of care consisted of three questions closely aligned with the Columbia-Suicide Severity Rating Scale (C-SSRS): 1) "Have you wished you were dead or wished you could go to sleep and not wake up?"; 2) "Have you had thoughts of harming yourself?"; 3) "In the last three months have you done anything, started to do anything or proposed to anything to end your life?" Individuals answering "yes" to number two were asked the remaining three questions of the suicidal ideation section of the C-SSRS and the attending physician was notified. Additionally, the patient's provider was asked to quantify their concern for a future suicide attempt by marking a 100-millimeter visual analog scale (VAS) in response to the question: "What is your level of suspicion that this patient will attempt suicide in the next 30 days?". Finally, the CAT-MHTM, as described below, also screened for suicide risk. Treating clinicians were informed of anyone who screened in the high-risk category for suicide using this tool. *Computer Adaptive Testing with the CAT-MH*TM

The CAT-MHTM ^{20, 23} is a suite of mental health computerized adaptive tests (CATs), that can be self-administered via any internet capable device (computer, tablet, smartphone), either in the clinic, ED, or remotely via a secure patient portal. The CAT-MHTM is unique in that unlike

traditional CATs developed for educational assessments that are based on unidimensional item response theory (IRT) and are only appropriate for simple constructs such as mathematical ability, the CAT-MHTM is based on multidimensional item response theory and is suitable for the measurement of complex constructs such as depression, anxiety, and suicidality. For a given construct (e.g., depression) the CAT-MHTM draws symptom items from a large bank of potential items that completely covers the latent variable of interest from the lowest to the highest levels of severity. The CAT begins by selecting an item from the middle of the severity continuum. Based on the item response, typically on a 5-point Likert scale, a provisional severity score and its uncertainty are computed. Based on that score, the next maximally informative item is selected and administered. Based on the response to the second item, the severity score and uncertainty are recomputed. The process continues until the uncertainty in the estimated score falls below 5 points on a 100-point scale.

In our study we included CATs for suicidality (CAT-SS²⁴), depression (CAT-DI²⁰), anxiety (CAT-ANX²⁵), PTSD (CAT-PTSD - an adaptive version of the 20-item PCL-5²⁶), and substance use disorder (CAT-SUD²⁷). The CAT-SUD also determines frequency of use of alcohol, sedatives/hypnotics, opioid analgesics, heroin/methadone, and cocaine/amphetamines. The suicide scale in the CAT-MHTM (the CAT-SS) was validated in two university hospital EDs,²⁴ and the depression test (CAT-DI) has been validated for use in EDs.¹² *Non-Adaptive Screening Tools*

We administered four additional validated self-administered screening tools. (1) The Generalized Anxiety Disorder 7-item scale (GAD-7) is a rapid screening tool for the presence of clinically significant anxiety. $^{28-31}$ The scores range from 0-21, with cut points of 5, 10, and 15 corresponding to mild, moderate, and severe anxiety, respectively. (2) The Patient Health Questionnaire 8 item scale (PHQ-8) is a rapid screening tool for the presence of clinically significant depression. $^{31-37}$ The scores range from 0-24, with cut points of 5, 10, 15, and 20 corresponding to mild, moderate, moderately severe, and severe depression, respectively. (3) The Patient Health Questionnaire-15 (PHQ-15) is used to detect participants at risk for somatoform disorders; $^{38, 39}$ it has cutoffs of 5, 10, and 15, corresponding to low, medium, and high somatic symptom severity. (4) The Pain Catastrophizing Score (PCS) is a 13-item self-administered tool used to quantify a person's thoughts and feelings when they have experienced pain. $^{40, 41}$ The maximum total score is 52 and total scores \geq 30 are considered clinically significant. 40

Analyses

We documented the percentage of patients endorsing different categories (e.g., normal, mild, moderate, severe) of the five domains assessed by the CAT-MHTM. We present this for all the patients, as well as a subgroup of patients who scored in the intermediate to high categories of suicidal risk. We then compared the identification of patients at risk for suicide using the CAT-MHTM with the standard ED procedures. To further examine the assessment of mental health and substance problems via the CAT-MHTM, we correlated the CAT-MHTM scores with clinician-reported suspected suicide and self-reported measures.

To determine the association between the number of ED visits in the year prior to enrollment and CAT-MHTM subscales, we conducted logistic regression analyses. The predictors, number of ED visits within the prior year, were dummy coded into three categories:

1) zero visits in the year prior, which served as the reference category, 2) one visit prior, and 3) two or more visits prior. We analyzed each CAT-MHTM subscale separately as a binary outcome, dichotomized suicide and substance use into low risk (0) and intermediate-high risk (1), depression and anxiety into normal/mild (0) and moderate/severe (1), and PTSD into no evidence (0) and possible/highly likely (1). We included the following demographic covariates: age, gender, ethnicity, race, marital status, and employment.

In order to examine the association between the CAT-MHTM subscales and subsequent ED visits within 30 days of ED enrollment date, we conducted logistic regression analyses adjusting for demographics. The predictors were each of the categorical risk levels for the CAT-MHTM subscales, which we dummy coded such that the lowest level of risk served as the reference category. Given the reduced sample size in the high-risk categories, we combined all the categories above low risk. For depression and anxiety subscales, mild was also included in the reference category. We dichotomized the outcome into not present (0) or any ED visit (1) within 30 days.

Sensitivity Analyses

We conducted three sensitivity analyses to examine the potential impact of analytical decisions on the results and interpretation. First, we predicted the continuous CAT-MHTM subscales from ED visits in the year prior to enrollment. We included an unstandardized and standardized outcome to examine the magnitude of the effects in terms of a single point increase on the 100-point scale and in terms of standard deviation units, respectively. Second, when

assessing the associations with mental health problems with subsequent ED visits, we utilized continuous, standardized CAT-MHTM subscales rather than utilizing categorical CAT-MHTM predictors. Third, we conducted ordinal logistic regression to predict ED visits within 30 days after enrollment to examine the association with each CAT-MHTM category.

Results

In the study, 1,854 patients were screened and approached for enrollment. Of those subjects who were approached for enrollment in the study, 828 (44.7%) underwent informed consent and were enrolled. Of those who consented, 97.3% (n=806) completed the CAT-MHTM. Reasons for lack of completion in the remaining 22 subjects included study withdrawal, interruptions related to clinical care such as procedures, and completion times over one hour. In order to conduct a complete case analysis, we dropped an additional 12 individuals with the following missing indicators: demographic variables, use of ED care within 30 days post-discharge, and the PTSD subscale on the CAT-MHTM. We also dropped one individual with an extreme outlier of ED care (i.e., 75 visits) within 30 days post-discharge and two individuals with invalid ages. The final analytic sample consisted of 794 individuals. See **Supplementary Figure 1** for the data flowchart. The median time for CAT-MHTM completion for the five domains was 9.7 minutes (IQR, 5.6 minutes).

Table 1 presents the overall breakdown of our population including frequency distribution of demographic, chief complaint, health history, suicide, admission, and questionnaire information of the subjects included in the sample. The average age was 43.7 years (Standard Deviation [SD], 16.3). Approximately 62% of the sample identified as female gender, 5% identified as Hispanic or Latino ethnicity, 51% identified as White/Caucasian, while 39% were Black/African American, 53% were single, 84% had a high school degree/GED or above, and 40% were employed full-time. The three most common chief complaints when participants presented in the ED were abdominal pain (21.0%), musculoskeletal pain (e.g., back, extremity, etc.) (13.2%), and chest pain (11.5%). The three most common health problems of which participants had a history included high blood pressure or hypertension (42.9%), anxiety (40.7%,), and depression (38.7%).

The mean score of the GAD-7 was 5.3 (SD, 5.9), PHQ-8 was 6.4 (SD, 5.8), PCS-13 was 10.7 (SD, 12.8), and PHQ-15 was 9.6 (SD, 5.6). The average number of ED visits to the

Midwestern healthcare network in 12 months prior to the participant's enrollment date was 2.1 (SD, 4.7) and within 30 days since the participant enrollment date was 0.3 (SD, 0.8).

Suicide risk severity was also assessed by the CAT-MHTM and the right-hand column in Table 1 presents the frequency distribution of demographic variables, chief complaint, medical history, self-report questionnaires, and admission information for those who screened intermediate-high-risk on the CAT-MHTM suicide severity rating (n=191). The frequencies of demographic, chief compliant, and medical information were similarly distributed for individuals who screened intermediate-high suicide risk as for the entire sample. Individuals who screened intermediate-high suicide risk had a higher proportion of those who endorsed history of PTSD or suicidal ideation, as well as a higher mean of prior ED visits within the past year, as compared to the entire sample.

Table 2 presents the frequency distribution of the CAT-MHTM subscales defined both categorically and continuously. The proportion of those who scored above the threshold of low risk/no evidence group for the following subscales were: 1) 24.1% for suicide, 2) 12.3% for PTSD, and 3) 20.4% for substance use. The proportion of those who scored above the threshold of normal/mild risk group for the following subscales were: 1) 8.3% for depression, and 2) 16.5% for anxiety. Across all categories, approximately 31.9% (n=253) of the sample screened above the threshold for at least one CAT-MHTM subscale and 20.7% (n=164) for two or more CAT-MHTM subscales. See **Supplementary Table 1** for the frequency distribution of use and abuse of specific substances.

To examine the overlap between suicide screens, **Table 3** presents the cross-tabulation between the CAT-MHTM positive suicide screen (i.e., those in the high-risk suicide severity category) and the ED's standard of care. Ten individuals screened positive on the CAT-MHTM suicide screen but only three of these screened positive by the standard of care ED screen. Thus, seven individuals were not identified via the standard of care screening. All seven identified participants were in the high-risk category on the CAT-MHTM suicide subscale. **Table 4** presents the Pearson correlations between the CAT-MHTM subscales and the clinician-rated suspected suicide rating and self-reported questionnaires. Each CAT-MHTM subscale, including suicidality, was weakly correlated with the clinician rating of suspected suicide, and was strongly correlated with the self-reported questionnaires indexing of anxiety, depression, pain catastrophizing, and physical symptoms.

Table 5 presents the prediction of dichotomous CAT-MHTM subscales from the number of ED visits in the year prior to enrollment. Individuals who had two or more ED visits in the prior year had a 51% increase in the odds of being in the intermediate-high suicide risk category (OR=1.51, 95% Confidence Interval [CI], 1.03-2.23) compared to those with zero prior ED visits. Odds ratios for the other CAT-MHTM subscales were the following: depression (OR, 1.61 [0.88-2.93]), anxiety (OR, 1.47 [0.94-2.29]), PTSD (OR, 2.49 [1.47-4.20]), and substance use disorder (OR, 1.55 [1.02-2.35]). Individuals with one visit to the ED in the prior year were not more likely to score higher on any of the CAT-MHTM subscales compared to those with zero visits. Table 6 presents the prediction of dichotomous ED visits (not present/any) within 30 days from CAT-MHTM subscales. Individuals who scored in the intermediate-high-suicide risk group had 71% greater odds of an ED visit within 30 days after their enrollment compared to those who scored as low risk (OR=1.71, 95% CI, 1.16, 2.53). The associations with the other domains assessed by the CAT-MHTM were not statistically significant and the confidence intervals around the estimates were quite wide.

Sensitivity Analyses

First, we predicted continuous CAT-MHTM subscales from visits to the ED within the 12 months prior to enrollment. The pattern of results was similar to the main analyses. For example, patients who visited the ED two or more times in the previous year scored 4.6 points higher on the continuous measure of suicide, which was a 0.25 standard deviation difference (Supplementary Table 2). Second, we predicted ED admissions 30 days after enrollment from standardized continuous CAT-MHTM subscales. The trend of results was similar to the main analyses (Supplementary Table 3). For suicide, each standard deviation increase in the suicide subscale was associated with a 19% increased odds of ED admission. Third, when conducting ordinal logistic regression to predict ED visits within 30 days after enrollment, the results followed a similar pattern as the main analyses, although the estimates were less statistically precise (Supplementary Table 4).

Discussion

This prospective observational study represents the most complete use of the validated computer adaptive tool (CAT-MHTM) in the ED environment for multidomain mental health screening in a broad random sample of patients presenting to a large urban emergency

department. According to the results of the CAT-MHTM screening, approximately one-third of the sample population (31.9%) had at least one high CAT-MHTM subscale and 20% of the sample had at least two high subscales scores. For example, 16.5% and 8.3% screened positive for moderate/severe anxiety and depression, respectively. The prevalence of clinically significant depression in this population (8.3%) by CAT-MHTM screening is similar to the prevalence of moderate to severe depression noted (7%) in another ED sample using the CAT-MHTM. Our population was primarily comprised of patients who presented without psychiatric complaint, and we know that a significant proportion of ED patients who are evaluated for non-psychiatric complaints (e.g., chest pain and abdominal pain) have comorbid mental health problems, which often remain undiagnosed during ED encounters. ^{13-15, 43}

Estimates suggest that approximately 1% of all US ED visits are related to suicidal ideation. deation. In our enrolled sample, three participants screened positive for suicidal ideation according to standard ED screening procedures as described above. While the CAT-MHTM correctly identified each of these individuals and categorized them as high risk, this tool detected seven additional high-risk individuals not flagged by standard of care screening. Notably, clinician report of suspected suicide was only very weakly correlated (r=0.11) with the CAT-MHTM index of suicidality. It is possible that patients felt more at ease disclosing their feelings via the tablet administered CAT-MHTM rather than directly to the nurse at check in or during the evaluation by the doctor. The results illustrate that universal screening protocols are minimally time-intensive (i.e., the median response time was roughly 2 minutes per each of the five included domains) and effective at identifying patients at high risk who would have otherwise been missed due to the non-psychiatric nature of their chief complaint. His is important, as a significantly higher proportion of those who screened intermediate to high suicide risk via the CAT-MHTM also self-reported more problems with anxiety, depression, PTSD, and substance use compared to the rest of the sample.

One of the aims of our study was to examine the relationship between mental illness and ED recidivism as mental illness has been shown to be a strong predictor of frequent ED use.^{11, 12, 45} In our study, compared to those with no visits in the 12 months prior to enrollment, those with two or more ED visits were significantly more likely to score in the high ranges for suicide risk, PTSD, and substance use on the CAT-MHTM. With regard to subsequent ED use in the 30 days post-enrollment, suicide risk (intermediate-high on the CAT-MHTM) was associated with an

increased likelihood of repeat ED utilization. Taken together, these results are consistent with prior literature showing that approximately 30% to 50% of these patients with frequent ED utilization have a mental health or substance use disorder. 11, 46-49

There are several important limitations to mention. We attempted to obtain a random sample of ED patients within our inclusion criteria with the aid of a random number generator in addition to adding evening and weekend screening, but this is only quasi-randomization. Additionally, since this study depended upon voluntary participation, it is unclear if those with underlying psychological conditions were more or less likely to volunteer to participate given either a willingness to disclose and seek help or concern regarding persistent mental health stigmas. In any case, these represent a form of selection bias which may actually underestimate the magnitude of impairing behavioral health conditions. With regards to the chief complaint, the overwhelming majority of complaints were somatic in nature. While we did not overtly seek to exclude those with mental health presentations (complaints of anxiety and depression), these patients are often triaged to the psychiatric observation rooms for close behavioral assessment, which would have effectively excluded them until they were moved out of those areas. As such, the results of this study apply primarily to patients receiving care in the ED for non-psychiatric complaints. Finally, our overall enrollment goals (1,000 patients) and ED recidivism targets (12 months) were curtailed by the institution of COVID-19 precautions and stay-at-home orders. We had planned to collect and analyze ED recidivism data for the 12 months post enrollment, but due to the extraordinary environmental and societal pressures applied by the broad stay-at-home orders during the COVID-19 pandemic²², we believed this would confound these data. Nonetheless, it is clear that there is a strong association between mental health issues and ED recidivism, which may benefit from screening tools such as the CAT-MHTM.

In the study we were able to demonstrate the use of the validated multidimensional CAT-MHTM to document the high rate of impairing mental health conditions and their associated ED utilization in a population of ED patients presenting largely for somatic complaints. Furthermore, in this population the CAT-MHTM performed superior to standard of care suicide screening in identifying more than three times the number of individuals at high risk for suicide. Future work should focus on assessing the ability of the multidomain CAT-MHTM in universal screening.

References

- 1. Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. National Center for Health Statistics. Updated July 19,2020. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf
- 2. Theriault KM, Rosenheck RA, Rhee TG. Increasing Emergency Department Visits for Mental Health Conditions in the United States. *J Clin Psychiatry*. Jul 28 2020;81(5)doi:10.4088/JCP.20m13241
- 3. Dark T, Flynn HA, Rust G, Kinsell H, Harman JS. Epidemiology of Emergency Department Visits for Anxiety in the United States: 2009-2011. *Psychiatr Serv*. Mar 1 2017;68(3):238-244. doi:10.1176/appi.ps.201600148
- 4. Ballou S, Mitsuhashi S, Sankin LS, et al. Emergency department visits for depression in the United States from 2006 to 2014. *Gen Hosp Psychiatry*. Jul-Aug 2019;59:14-19. doi:10.1016/j.genhosppsych.2019.04.015
- 5. Capp R, Hardy R, Lindrooth R, Wiler J. National Trends in Emergency Department Visits by Adults With Mental Health Disorders. *J Emerg Med.* Aug 2016;51(2):131-135.e1. doi:10.1016/j.jemermed.2016.05.002
- 6. Hill T, Jiang Y, Friese CR, Darbes LA, Blazes CK, Zhang X. Analysis of emergency department visits for all reasons by adults with depression in the United States. *BMC Emerg Med.* Jun 22 2020;20(1):51. doi:10.1186/s12873-020-00347-6
- 7. Boudreaux ED, Camargo CA, Jr., Arias SA, et al. Improving Suicide Risk Screening and Detection in the Emergency Department. *Am J Prev Med.* Apr 2016;50(4):445-453. doi:10.1016/j.amepre.2015.09.029
- 8. Weiss AJ, Barrett ML, Heslin KC, Stocks C. Trends in Emergency Department Visits Involving Mental and Substance Use Disorders, 2006–2013: Statistical Brief #216. *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Agency for Healthcare Research and Quality (US); 2006.
- 9. Owens PL, Fingar KR, Heslin KC, Mutter R, Booth CL. Emergency Department Visits Related to Suicidal Ideation, 2006–2013: Statistical Brief #220. *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Agency for Healthcare Research and Quality (US); 2006.
- 10. Karaca Z, Moore BJ. Costs of Emergency Department Visits for Mental and Substance Use Disorders in the United States, 2017: Statistical Brief #257. *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Agency for Healthcare Research and Quality (US); 2006.
- 11. Niedzwiecki MJ, Sharma PJ, Kanzaria HK, McConville S, Hsia RY. Factors Associated With Emergency Department Use by Patients With and Without Mental Health Diagnoses. *JAMA Netw Open*. Oct 5 2018;1(6):e183528. doi:10.1001/jamanetworkopen.2018.3528
- 12. Beiser DG, Ward CE, Vu M, Laiteerapong N, Gibbons RD. Depression in Emergency Department Patients and Association with Healthcare Utilization. *Acad Emerg Med.* Aug 2019;28(8):878-888. doi:10.1111/acem.13726
- 13. Downey LV, Zun LS, Burke T. Undiagnosed mental illness in the emergency department. *J Emerg Med.* Nov 2012;43(5):876-82. doi:10.1016/j.jemermed.2011.06.055
- 14. Claassen CA, Larkin GL. Occult suicidality in an emergency department population. *Br J Psychiatry*. Apr 2005;186:352-3. doi:10.1192/bjp.186.4.352
- 15. Ilgen MA, Walton MA, Cunningham RM, et al. Recent suicidal ideation among patients in an inner city emergency department. *Suicide Life Threat Behav*. Oct 2009;39(5):508-17. doi:10.1521/suli.2009.39.5.508

- 16. Betz ME, Wintersteen M, Boudreaux ED, et al. Reducing Suicide Risk: Challenges and Opportunities in the Emergency Department. *Ann Emerg Med.* Dec 2016;68(6):758-765. doi:10.1016/j.annemergmed.2016.05.030
- 17. Heyland M, Delaney KR, Shattell M. Steps to Achieve Universal Suicide Screening in Emergency Departments: A Call to Action. *J Psychosoc Nurs Ment Health Serv*. Oct 1 2018;56(10):21-26. doi:10.3928/02793695-20180503-03
- 18. Ahmedani BK, Simon GE, Stewart C, et al. Health care contacts in the year before suicide death. *J Gen Intern Med.* Jun 2014;29(6):870-7. doi:10.1007/s11606-014-2767-3
- 19. Gairin I, House A, Owens D. Attendance at the accident and emergency department in the year before suicide: retrospective study. *Br J Psychiatry*. Jul 2003;183:28-33. doi:10.1192/bjp.183.1.28
- 20. Gibbons RD, Weiss DJ, Pilkonis PA, et al. Development of a computerized adaptive test for depression. *Arch Gen Psychiatry*. Nov 2012;69(11):1104-12. doi:10.1001/archgenpsychiatry.2012.14
- 21. Regenstrief Institute Data Services: Indiana Network for Paient Care. Accessed May 3, 2021, https://www.regenstrief.org/rds/data/
- 22. Ziedan E, Simon KI, Wing C. Effects of state COVID-19 closure policy on NON-COVID-19 health care utilization. *NBER Working Paper*. 2020;(w27621)
- 23. Gibbons RD, Weiss DJ, Frank E, Kupfer D. Computerized Adaptive Diagnosis and Testing of Mental Health Disorders. *Annu Rev Clin Psychol.* 2016;12:83-104. doi:10.1146/annurev-clinpsy-021815-093634
- 24. Gibbons RD, Kupfer D, Frank E, Moore T, Beiser DG, Boudreaux ED. Development of a Computerized Adaptive Test Suicide Scale-The CAT-SS. *J Clin Psychiatry*. Nov/Dec 2017;78(9):1376-1382. doi:10.4088/JCP.16m10922
- 25. Gibbons RD, Weiss DJ, Pilkonis PA, et al. Development of the CAT-ANX: a computerized adaptive test for anxiety. *Am J Psychiatry*. Feb 2014;171(2):187-94. doi:10.1176/appi.ajp.2013.13020178
- 26. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*. Dec 2015;28(6):489-98. doi:10.1002/jts.22059
- 27. Gibbons RD, Alegria M, Markle S, et al. Development of a computerized adaptive substance use disorder scale for screening and measurement: the CAT-SUD. *Addiction*. Jul 2020;115(7):1382-1394. doi:10.1111/add.14938
- 28. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med.* May 22 2006;166(10):1092-7. doi:10.1001/archinte.166.10.1092
- 29. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry*. Mar-Apr 2016;39:24-31. doi:10.1016/j.genhosppsych.2015.11.005
- 30. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med*. Mar 06 2007;146(5):317-25.
- 31. Ruiz MA, Zamorano E, Garcia-Campayo J, Pardo A, Freire O, Rejas J. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. *J Affect Disord*. Feb 2011;128(3):277-86. doi:10.1016/j.jad.2010.07.010

- 32. Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. *Psychiatric Annals*. 2002;32(9):509-515.
- 33. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. *Journal of general internal medicine*. 2001;16:606-613.
- 34. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med*. Nov 2007;22(11):1596-602. doi:10.1007/s11606-007-0333-y
- 35. Hyphantis T, Kotsis K, Kroenke K, et al. Lower PHQ-9 cutpoint accurately diagnosed depression in people with long-term conditions attending the Accident and Emergency Department. *J Affect Disord*. May 1 2015;176:155-63. doi:10.1016/j.jad.2015.01.062
- 36. Meltzer AC, Bregman B, Blanchard J. Depression is associated with repeat emergency department visits in patients with non-specific abdominal pain. *West J Emerg Med*. May 2014;15(3):325-8. doi:10.5811/westjem.2013.7.15635
- 38. Kocalevent RD, Hinz A, Brähler E. Standardization of a screening instrument (PHQ-15) for somatization syndromes in the general population. *BMC Psychiatry*. Mar 20 2013;13:91. doi:10.1186/1471-244x-13-91
- 39. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med.* Mar-Apr 2002;64(2):258-66. doi:10.1097/00006842-200203000-00008
- 40. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychological assessment*. 1995;7(4):524-532. doi:10.1037/1040-3590.7.4.524
- 41. Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. *Expert Rev Neurother*. May 2009;9(5):745-58. doi:10.1586/ern.09.34
- 42. Beiser DG, Ward CE, Vu M, Laiteerapong N, Gibbons RD. Screening for Depression in Emergency Department Patients and Relationship to Health Care Utilization. 2016:
- 43. Abar B, Holub A, Lee J, DeRienzo V, Nobay F. Depression and Anxiety Among Emergency Department Patients: Utilization and Barriers to Care. *Acad Emerg Med.* Oct 2017;24(10):1286-1289. doi:10.1111/acem.13261
- 44. Miller IW, Camargo CA, Jr., Arias SA, et al. Suicide Prevention in an Emergency Department Population: The ED-SAFE Study. *JAMA psychiatry*. Jun 1 2017;74(6):563-570. doi:10.1001/jamapsychiatry.2017.0678
- 45. Colligan EM, Pines JM, Colantuoni E, Howell B, Wolff JL. Risk Factors for Persistent Frequent Emergency Department Use in Medicare Beneficiaries. *Ann Emerg Med.* Jun 2016;67(6):721-729. doi:10.1016/j.annemergmed.2016.01.033
- 46. Hunt KA, Weber EJ, Showstack JA, Colby DC, Callaham ML. Characteristics of frequent users of emergency departments. *Ann Emerg Med.* Jul 2006;48(1):1-8. doi:10.1016/j.annemergmed.2005.12.030
- 47. Hardy M, Cho A, Stavig A, et al. Understanding Frequent Emergency Department Use Among Primary Care Patients. *Popul Health Manag*. Feb 2018;21(1):24-31. doi:10.1089/pop.2017.0030
- 48. Ondler C, Hegde GG, Carlson JN. Resource utilization and health care charges associated with the most frequent ED users. *Am J Emerg Med*. Oct 2014;32(10):1215-9. doi:10.1016/j.ajem.2014.07.013

49. Schmidt EM, Behar S, Barrera A, Cordova M, Beckum L. Potentially Preventable Medical Hospitalizations and Emergency Department Visits by the Behavioral Health Population. *J Behav Health Serv Res.* Jul 2018;45(3):370-388. doi:10.1007/s11414-017-9570-y

 $\textbf{Table 1}. \ \text{Frequency distribution of intake variables for entire sample and sample screening intermediate-high suicide risk on CAT-MH^{TM}$

SUICIDE TISK OF CAT-MH		
	Individuals consenting	Individuals screened
	for CAT-MH TM	intermediate-high CAT-
	(N=794)	MH TM suicide risk
		(N=191)
Demographic Information	$N\left(\%\right)^{a}$	N (%) ^b
Gender		
Female	492 (62.0)	125 (65.5)
Male	301 (37.9)	66 (34.6)
Other	1 (0.1)	0 (0)
Ethnicity		
Hispanic or Latino	42 (5.3)	11 (5.8)
Not Hispanic or Latino	725 (91.3)	174 (91.1)
Unknown or not reported	27 (3.4)	6 (3.1)
Race		
White	413 (52.0)	105 (55.0)
Black or African American	316 (39.8)	65 (34.0)
Asian	3 (0.4)	0 (0)
American Indian/Alaska Native	6 (0.8)	2 (1.1)
Native Hawaiian or Other Pacific Islander	0 (0)	0 (0)
More than one race	36 (4.5)	15 (7.9)
Other	20 (2.5)	4 (2.1)
Marital Status	` ,	, ,
Single	422 (53.2)	101 (52.9)
Married	224 (28.2)	38 (19.9)
Separated	21 (2.6)	9 (4.7)
Divorced	91 (11.5)	31 (16.2)
Widowed	36 (4.5)	12 (6.3)
Education	,	,
Some high school	126 (15.9)	43 (22.5)
High school	230 (29.0)	39 (20.4)
GED	42 (5.3)	12 (6.3)
Some college	210 (26.5)	51 (26.7)
Graduate college	149 (18.8)	38 (19.9)
Graduate/professional school	37 (4.7)	8 (4.2)
Employment		2 (11-)
Employed full-time	318 (40.1)	63 (33.0)
Employed part-time	86 (10.8)	26 (13.6)
Student and working	19 (2.4)	3 (1.6)
Student and not working	19 (2.4)	4 (2.1)
Homemaker	19 (2.4)	7 (3.7)
Unemployed	99 (12.5)	28 (14.7)
Retired	80 (10.1)	10 (5.2)
Disabled	154 (19.4)	50 (26.2)
Chief Complaint	13 (17.1)	30 (20.2)
Abdominal pain	167 (21.0)	45 (23.6)
Abnormal lab/test results	3 (0.4)	2 (1.1)
Abnormal vital signs (heart rate, blood pressure, etc.)	14 (1.8)	1 (0.5)
Allergic reaction	3 (0.4)	1 (0.5)
Anxiety	3 (0.4)	2 (1.1)
Chest pain	91 (11.5)	17 (8.9)
Ear, Nose, and Throat complaint	28 (3.5)	6 (3.1)
Eye complaint	7 (0.9)	0 (0.1)
Facial pain	8 (1.0)	2 (1.1)
Fever/chills/sepsis	12 (1.5)	0 (0)
rever/ellilis/sepsis	12 (1.3)	0 (0)

Other musculoskeletal pain (back, extremity, etc.)	105 (13.2)	25 (13.1)
Gastrointestinal problem (vomiting, diarrhea, etc.)	51 (6.4)	14 (7.3)
Genitourinary problem (kidney complaints, etc.)	14 (1.8)	4 (2.1)
Headache	26 (3.3)	5 (2.6)
Medical screen/evaluation	10 (1.3)	3 (1.6)
Neurological complaint (seizure, focal weakness, etc.)	18 (2.3)	4 (2.1)
Obstetric-Gynecological complaint	21 (2.6)	7 (3.7)
Post-operative complication	4 (0.5)	2 (1.1)
Respiratory problem (cough, asthma, shortness of breath)	78 (9.8)	15 (7.9)
Sickle cell crisis	11 (1.4)	1 (0.5)
Skin/soft tissue infection or complaint	22 (2.8)	6 (3.1)
Substance use	1 (0.1)	1 (0.5)
Trauma (motor vehicle accident, fall, assault, etc.)	34 (4.3)	5 (2.6)
Weakness/fatigue and dizziness	44 (5.5)	14 (7.3)
Miscellaneous	16 (2.0)	8 (4.2)
Invalid	2 (0.3)	1 (0.5)
Missing	1 (0.1)	0 (0)
1411351115	1 (0.1)	0 (0)
II 4 - II - 4 I - 6 4		
Health History Information		
Currently have a primary care physician	580 (73.0)	136 (71.2)
History of:		
Asthma, emphysema, chronic bronchitis	251 (31.6)	75 (39.3)
High blood pressure or hypertension	341 (42.9)	82 (42.9)
High blood sugar or diabetes	175 (22.0)	46 (24.1)
Arthritis or rheumatism	226 (28.3)	63 (33.3)
Heart attack, angina, heart failure, or other	140 (17.6)	36 (18.9)
types of heart disease	140 (17.0)	30 (10.5)
	102 (12.8)	40 (20 0)
Stroke, seizures, Parkinson's disease, or	102 (12.8)	40 (20.9)
another neurological condition	40.47.0	40 (40)
Liver disease	40 (5.0)	12 (6.3)
Kidney or renal disease	82 (10.3)	27 (14.4)
Cancer diagnosed or treated in the last 3 years	58 (7.3)	12 (6.3)
Anxiety	323 (40.7)	136 (71.2)
Depression	307 (38.7)	141 (73.8)
PTSD	129 (16.2)	67 (35.1)
Suicidal thoughts or attempt	58 (7.3)	45 (23.6)
Current use of:	20 (1.5)	15 (25.0)
Tobacco	269 (33.9)	88 (46.1)
Alcohol ≥4 times/week	99 (12.5)	28 (14.7)
Marijuana	163 (20.5)	73 (38.2)
Cocaine	13 (1.6)	5 (2.6)
Heroin	3 (0.4)	1 (0.5)
Other	13 (1.6)	7 (3.7)
Symptom Questionnaire Information	N (%)	N (%) ^b
•		
GAD-7 (Generalized Anxiety Disorder)		
Minimal (0-4)	454 (57.2)	22 (11.5)
Mild (5-9)	184 (23.2)	60 (31.4)
Moderate (10-14)	* *	40 (20.9)
	73 (9.2)	` /
Severe (≥15)	83 (10.6)	69 (36.1)
PHQ-8 (Depression)	000 (70 4)	·
Minimal (0-4)	398 (50.1)	15 (7.9)
Mild (5-9)	188 (23.7)	33 (17.3)
Moderate (10-14)	118 (14.9)	61 (31.9)
Moderately severe (15-19)	58 (7.3)	51 (26.7)
* '	` /	` '

Severe (≥20)	32 (4.0)	31 (16.2)
PCS-13 (Pain Catastrophizing)		
None/Mild (0-29)	705 (88.8)	124 (64.9)
Clinically significant (≥30)	89 (11.2)	67 (35.1)
PHQ-15 (Somatic Symptoms)		
Very Low (0-4)	$135(19.3)^{c}$	$10(6.0)^{d}$
Low (5-9)	236 (33.8) ^c	$35(21.1)^{d}$
Medium (10-14)	195 (27.9) ^c	51 (30.7) ^d
High (≥15)	133 (19.0) ^c	$70(42.1)^{d}$
_	M (SD) (range)	M (SD) (range)
VAS Suspected suicide within next 30 days	5.0 (8.9) (0-74)	6.3 (11.3) (0-74)
Admission Information	M (SD) (range)	M (SD) (range)
	() () (` / ` U /
Number of ED visits within 12 months prior to enrollment	2.1 (4.7) (0-76)	3.3 (7.6) (0-76)
date		
Number of repeated ED visits in 30 days since enrollment	0.3 (0.8) (0-9)	0.5 (1.1) (0-7)
date		

^aBased on 794 unique individuals. Rounded to nearest tenth; may not equal 100%. ^bBased on 191 individuals. ^cBased on 699 unique individuals. ^dBased on 166 individuals.

Table 2. Frequency distribution of CAT-MHTM variables for entire sample and those who screened intermediate-high suicide risk on CAT-MHTM

	Individuals	Individuals screened
	consenting for CAT-MH TM	intermediate-high CAT-MH TM suicide
	-	risk ^b
Categorical Subscales	N (%)	N (%)
Depression Subscale		
Normal	433 (54.5)	9 (4.7)
Mild	295 (37.2)	120 (62.8)
Moderate	35 (4.4)	32 (16.8)
Severe	31 (3.9)	30 (15.7)
Anxiety Subscale		
Normal	537 (67.6)	28 (14.7)
Mild	126 (15.9)	52 (27.2)
Moderate	69 (8.7)	54 (28.3)
Severe	62 (7.8)	57 (29.8)
PTSD Subscale		
No evidence	696 (87.7)	104 (54.5)
Possible	74 (9.3)	63 (33.0)
Highly likely	24 (3.0)	24 (12.6)
Substance Use Subscale		
Low Risk	632 (79.6)	73 (38.2)
Intermediate Risk	143 (18.0)	106 (55.5)
High Risk	19 (2.4)	12 (6.3)
	M (SD)	M (SD)
Continuous Subscales	Skewness; Kurtosis	Skewness; Kurtosis
Depression Subscale	34.1 (21.0)	60.2 (15.3)
-	0.5; -0.2	0.3; -0.1
Anxiety Subscale	26.0 (23.6)	54.5 (20.2)
	0.9; < 0.1	-0.1; 0.1
PTSD Subscale	29.8 (20.8)	54.1 (14.4)
	0.3; -0.4	0.3; 0.6
Substance Use Subscale	34.6 (18.6)	52.9 (10.6)
	-0.1; -0.5	0.5; 0.6

Rounded to the nearest tenth, may not equal 100%. ^aBased on 794 unique individuals who completed the CAT-MH study protocol. ^bBased on 191 unique individuals who screened in the intermediate or high risk group on suicide severity subscale on the CAT-MH.

Table 3. Cross-tabulation between suicide screen in ED and CAT-MH

	CAT-MH Suicid	e Screen (N, %)
	Negative	Positive ¹
ED Standard Care Suicide Screening		
Positive	0 (0)	3 (0.38)
Negative	760 (95.72)	7 (1.01)
Not Recorded	23 (2.90)	0 (0)

Derived from 794 unique individuals. CAT-MH suicide screen based on suicide severity. ¹ Individuals who screened positive were in the high-risk suicide severity group.

Table 4. Pearson correlation between CAT-MH subscales, clinician-reported suicidality and other self-report measures

	Clinician Rating of	Sum GAD-7	Sum PHQ-8	Sum of Pain	Sum of Physical
	Suspected Suicide in	r^{a}	r^{a}	Catastrophizing	Symptoms
CAT-MH Subscale	Next 30 Days ^a			r^{a}	r^{b}
Suicide Subscale	0.11	0.73	0.79	0.63	0.50
Depression Subscale	0.14	0.72	0.78	0.63	0.53
Anxiety Subscale	0.12	0.76	0.74	0.62	0.53
PTSD Subscale	0.12	0.73	0.70	0.57	0.49
Substance Use Subscale	0.09	0.62	0.66	0.54	0.49

All p-values <0.01. ^aBased on 794 unique individuals. ^bBased on 699 unique individuals.

Table 5. Prediction of CAT-MH from prior year ED visits using logistic regression

	Suicide Subscale	Depression Subscale	Anxiety Subscale	PTSD Subscale	Substance Use Subscale
Visits ED year prior	OR (95% CI; p-value)	OR (95% CI; p-value)			
0	REF	REF	REF	REF	REF
1	0.85 (0.53-1.37; p=0.50)	1.03 (0.49-2.19; p=0.94)	1.02 0.60-1.76; p=0.93)	1.54 (0.82-2.89; p=0.18)	1.14 (0.69-1.86; p=0.62)
≥2	1.51 (1.03-2.23; p=0.04)	1.61 (0.88-2.93; p=0.12)	1.47 (0.94-2.29; p=0.09)	2.49 (1.47-4.20; p<0.001)	1.55 (1.02-2.35; p=0.04)

Derived from 794 unique individuals. Demographic variables included are age, gender, ethnicity, race, marital status, and employment. Each CAT-MH subscale was dichotomized: suicide subscale 0=low risk, 1=intermediate-high risk; depression subscale 0=normal-mild; 1=moderate-severe; PTSD subscale 0=no evidence, 1=possible-highly likely; substance use subscale 0=low risk, 1=intermediate-high risk.

Table 6. Prediction of ED visits within 30 days using logistic regression with combined categorical predictors

regression with combined catego	orieur predictors
	OR (95% CI; p-value)
Suicide	
Low Risk	REF
Intermediate-High Risk	1.71 (1.16-2.53; p=0.01)
Depression	
Normal-Mild	REF
Moderate-Severe	1.06 (0.58-1.94; p=0.86)
Anxiety	
Normal-Mild	REF
Moderate-Severe	1.20 (0.77-1.89; p=0.43)
PTSD	
No Evidence	REF
Possible-Highly Likely	1.13 (0.67-1.89; p=0.65)
Substance Use	
Low Risk	REF
Intermediate-High Risk	0.95 (0.62-1.47; p=0.83)
B : 16 504 : : 1::1 1 E	5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

Derived from 794 unique individuals. ED visits dichotomized into not present/any (0/1). Demographic variables included are age, gender, ethnicity, race, marital status, and employment.

Supplementary Material


Supplementary Figure 1. Data flowchart.

Supplementary Table 1. Frequency distribution of CAT-MH specific substance use variables.

Supplementary Table 2. Prediction of CAT-MH from prior year ED visits using linear regression.

Supplementary Table 3. Prediction of ED visits within 30 days using logistic regression with continuous predictors.

Supplementary Table 4. Prediction of ED visits in prior from CAT-MH subscales using ordinal logistic regression.



Supplementary Figure 1. Data flowchart

Supplementary Table 1. Frequency distribution of CAT-MH specific substance use variables

Categorical Subscales	N (%)
Alcohol Use in Past Month	. (**)
0 Days	647 (81.5)
1-10 Days	75 (9.5)
11-20 Days	19 (2.4)
21-30 Days	53 (6.7)
Sedatives/Hypnotic Use in Past Month	. ,
0 Days	726 (91.4)
1-10 Days	31 (3.9)
11-20 Days	8 (1.0)
21-30 Days	29 (3.7)
Opioids/Analgesic Use in Past Month	
0 Days	489 (61.6)
1-10 Days	251 (31.6)
11-20 Days	31 (3.9)
21-30 Days	23 (2.9)
Heroin/Methadone Use in Past Month	
0 Days	786 (99.0)
1-10 Days	4 (0.5)
11-20 Days	1 (0.1)
21-30 Days	3 (0.4)
Cocaine/Amphetamine Use in Past Month	
0 Days	767 (96.6)
1-10 Days	18 (2.3)
11-20 Days	3 (0.4)
21-30 Days	6 (0.8)

Based on 794 unique individuals who completed the CAT-MH study protocol.

Supplementary Table 2. Prediction of CAT-MH from prior year ED visits using linear regression

1						
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		Suicide Subscale	Depression Subscale	Anxiety Subscale	PTSD Subscale	Substance Use Subscale
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Visits ED year prior					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			Unsta	andardized regression	; b (SE)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0	REF	REF	REF	REF	REF
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1	1.42 (1.69)	-0.15 (1.93)	1.38 (2.16)	0.34 (1.91)	1.13 (1.69)
0 REF REF REF REF REF REF 1 0.08 (0.09) -0.01 (0.09) 0.06 (0.09) 0.02 (0.09) 0.06 (0.09)	≥2	4.63 (1.50)*	5.94 (1.73)*	6.72 (1.93)*	4.70 (1.70)*	5.44 (1.51)*
1 0.08 (0.09) -0.01 (0.09) 0.06 (0.09) 0.02 (0.09) 0.06 (0.09)			Stan	dardized regression;	 β (SE)	
	0	REF	REF	REF	REF	REF
≥ 2 0.25 (0.08)* 0.28 (0.08)* 0.28 (0.08)* 0.23 (0.08)* 0.29 (0.08)*	1	0.08 (0.09)	-0.01 (0.09)	0.06 (0.09)	0.02 (0.09)	0.06 (0.09)
	≥2	0.25 (0.08)*	0.28 (0.08)*	0.28 (0.08)*	0.23 (0.08)*	0.29 (0.08)*

Derived from 794 unique individuals. * Statistically significant at p<0.05. Demographic variables included are age, gender, ethnicity, race, marital status, and employment.

Supplementary Table 3. Prediction of ED visits within 30 days using logistic regression with continuous predictors

	1
CAT-MH Subscale	OR (95% CI; p-value) ^a
Suicide	1.19 (1.01-1.41; p=0.04)
Depression	1.16 (0.97-1.37; p=0.10)
Anxiety	1.17 (0.99-1.39; p=0.07)
PTSD	1.06 (0.89-1.26; p=0.52)
Substance Use	1.17 (0.97-1.39; p=0.10)

Derived from 794 unique individuals. ED visits dichotomized into not present/any (0/1). Continuous predictors standardized. Demographic variables included are age, gender, ethnicity, race, marital status, and employment.

Supplementary Table 4. Prediction of ED visits in prior year from CAT-MH subscales using ordinal logistic regression

regression	
	OR (95% CI; p-value)
	ED visits within 30 days ^a
Suicide	
Low Risk	REF
Intermediate Risk	1.34 (0.98-1.83; p=0.07)
High Risk	1.59 (0.50-5.05; p=0.43)
Depression	•
Normal	REF
Mild	1.49 (1.13-1.97; p=0.01)
Moderate	1.33 (0.69-2.53; p=0.39)
Severe	2.04 (1.04-4.02; p=0.04)
Anxiety	
Normal	REF
Mild	1.59 (1.11-2.28; p=0.01)
Moderate	1.52 (0.95-2.42; p=0.08)
Severe	_
	1.59 (0.97-2.60;p=0.07)
PTSD	
No Evidence	REF
Possible	1.99 (1.27-3.13; p=0.003)
Highly Likely	
	2.58 (1.20-5.56; p=0.02)
Substance Use	
Low Risk	REF
Intermediate Risk	1.35 (0.96-1.90; p=0.08)
High Risk	
	1.81 (0.77-4.25; p=0.17)

Derived from 794 unique individuals. Demographic variables included are age, gender, ethnicity, race, marital status, and employment. $^{\rm a}$ Ordinal outcome categories included 0, 1, 2, and \geq 3.